logo
Medtronic Announces Intent To Spin Diabetes Business

Medtronic Announces Intent To Spin Diabetes Business

Forbesa day ago

(Photo Illustration by)
Deal OverviewOn May 21, 2025, Medtronic plc (NYSE: MDT; $87.44, Market Capitalization: $112.1 billion), a global leader in medical technology, announced its intent to spin off its Diabetes business into a standalone entity (New Diabetes Company). This strategic move is designed to streamline Medtronic's portfolio, sharpen its focus on high-margin growth areas, and unlock shareholder value.
Post spin-off, Medtronic (RemainCo) will continue to operate as a diversified MedTech innovator, concentrating on its core franchises in cardiovascular, neuroscience, surgical, and medical-surgical technologies. Further, the company aims to accelerate growth through innovation in areas like pulsed field ablation, renal denervation, soft tissue robotics, and neuromodulation. Meanwhile, the New Diabetes Company (NewCo) will be offering a complete ecosystem for intensive insulin management, including insulin pumps, continuous glucose monitoring (CGM), and digital health solutions. The separation is expected to be completed within 18 months, primarily through a capital markets transaction, with a preferred path of an initial public offering (IPO) followed by a split-off. The transaction is expected to be tax-free to Medtronic shareholders for US federal income tax purposes. The separation will include the Diabetes business employees, product portfolio, pipeline, intellectual property, strategic partnerships, and global manufacturing facilities.
Medtronic Price Performance Spin-Off Details and Top 5 Shareholders
The transaction is anticipated to be accretive to Medtronic's gross and operating margins, and earnings per share, while enabling the NewCo to pursue focused innovation and growth strategies tailored to the diabetes market. It is also expected to provide the ability to retire Medtronic shares outstanding without reducing cash, resulting in EPS accretion and a reduction in the dividend liability for Medtronic, enabling increased growth-accretive investment. Medtronic expects its dividend per share to remain unchanged pre- and post-transaction with no change to its dividend policy.
The spin-off is subject to customary regulatory approvals, board consent, and market conditions. Que Dallara, current EVP and president of Medtronic Diabetes, will become CEO of New Diabetes Company.
Goldman Sachs & Co. LLC and BofA Securities, Inc. are acting as financial advisors to Medtronic in its review of strategic alternatives for the New Diabetes Company.
Key Data
Deal Rationale
Medtronic, a global leader in MedTech, is planning to spin off its Diabetes business into a standalone entity, as part of a strategic move to sharpen its focus on higher-margin, faster-growing segments such as Cardiovascular, Neuroscience, and Medical-Surgical, which together account for over 90.0% of its total revenues.
The Diabetes segment, contributing approximately $2.5 billion in FY25 (about 8.0% of Medtronic's total $32.4 billion in revenue), has consistently underperformed over the past five years, with a revenue CAGR of just ~1.4% compared to Medtronic's overall ~2.9% CAGR. Segment profitability has also lagged: while Medtronic's overall operating margin stands at ~15.9%, the diabetes unit has been a drag, reportedly generating operating losses in the low teens in its core U.S. market. In FY19, the segment posted a strong operating margin of 30.9% but steadily declined to 24.8–24.9% through FY21 and FY22, before dropping significantly to 15.8% in FY25.
Multiple headwinds contributed to this underperformance, including FDA regulatory setbacks, such as the 2021 warning letter and delayed approval of the MiniMed 780G insulin pump and Guardian 4 sensor, alongside intensifying competition from more agile players like Dexcom, Abbott, Tandem, and Insulet. These rivals outpaced Medtronic with faster innovation in continuous glucose monitoring (CGM) and closed loop insulin delivery systems. Furthermore, the rising adoption of GLP-1 receptor agonists (e.g., Ozempic, Mounjaro) is shifting treatment paradigms, particularly for Type 2 diabetes, reducing demand for insulin pumps.
Despite a recent rebound, with the diabetes segment growing ~10.7% YoY in FY25 and six consecutive quarters of double-digit growth, the improvement is seen as insufficient to offset the structural challenges and lower returns relative to the rest of Medtronic's portfolio. By spinning off the diabetes business, Medtronic aims to lift its gross margin by approximately 50 basis points, adjusted operating margins by approximately 100 basis points, and be immediately accretive to adjusted EPS.
As per management, following this separation, Medtronic is expected to increase focus on innovation-driven growth and category leadership for healthcare systems and physician customers. The company will have enhanced benefit from its scale and strategic commercial, manufacturing, and technology synergies.
On the other hand, this separation is expected to enable more focused investment into New Diabetes Company's pipeline, as well as manufacturing scale and automation, positioning the company for success in Automated Insulin Delivery and Smart MDI, while driving margin expansion over time.
At the same time, it will create an independent, scaled leader in Diabetes, focused on accelerating innovation and differentiated as the only company to commercialize a complete ecosystem to address intensive insulin management.
The separation is also expected to unlock value for Medtronic and its shareholders, as it creates a New Diabetes Company shareholder base more aligned with its financial profile.
Medtronic plc is a global healthcare technology leader that designs and manufactures medical devices and therapies to treat a wide range of chronic and acute health conditions. The company operates in over 150 countries and focuses on improving patient outcomes through innovation in areas such as AI, robotics, and data-driven care.
Medtronic's operations are structured into four major segments, each addressing a distinct area of healthcare technology. The Cardiovascular segment includes heart rhythm devices, heart valves, and vascular therapies for treating cardiac and circulatory conditions. The Neuroscience segment offers spinal implants, stroke treatment devices, and neuromodulation systems for managing neurological and musculoskeletal disorders. The Medical Surgical segment provides surgical tools, robotic-assisted systems, and patient monitoring technologies, while the Diabetes segment delivers insulin pumps, continuous glucose monitoring systems, and smart insulin pens to help manage diabetes effectively.
Cardiovascular: The Cardiovascular segment is dedicated to treating heart and vascular diseases through advanced medical technologies. It includes three subsegments: Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Coronary & Peripheral Vascular. This segment offers pacemakers, implantable defibrillators, heart valves, ablation systems, and vascular stents. In FY25, it generated $12.4 billion in revenue (37.2% of total revenue), growing 5.5%. Medtronic continues to lead in innovations like leadless pacing and pulsed field ablation, addressing both chronic and acute cardiac conditions globally.
• Cardiac Rhythm & Heart Failure (CRHF): CRHF focuses on devices tha manage abnormal heart rhythms and heart failure. It includes pacemakers like the Micra leadless system, implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT) devices, and insertable cardiac monitors. The segment also includes cardiac ablation systems and remote monitoring services.• Structural Heart & Aortic (SHA): SHA provides solutions for heart valve disorders and aortic diseases. It includes transcatheter aortic valve replacement (TAVR) systems like Evolut FX, surgical heart valves, perfusion systems, and endovascular stent grafts. These devices are used in both minimally invasive and open-heart procedures.• Coronary & Peripheral Vascular (CPV): CPV delivers therapies for coronary artery disease and peripheral vascular conditions. It includes druge luting stents (e.g., Onyx Frontier), angioplasty balloons, renal denervation systems (e.g., Symplicity Spyral), and venous disease treatments like VenaSeal.
Neuroscience: The Neuroscience segment addresses neurological and musculoskeletal disorders through surgical and therapeutic technologies. It includes Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation. This segment integrates robotics, AI, and navigation systems to improve surgical precision and patient outcomes. In FY25, it generated $9.8 billion in revenue (29.4% of total revenue), growing 4.7%. Medtronic's innovations in spine surgery, stroke treatment, and neuromodulation continue to drive global adoption.
• Cranial & Spinal Technologies (CST): CST develops surgical solutions for spine and cranial procedures. It includes implants, biologics, and enabling technologies like Mazor robotics, StealthStation navigation, and UNiD AI-driven planning. These tools help surgeons perform complex procedures with greater accuracy.• Specialty Therapies: This subsegment includes neurovascular, ENT (ear, nose, and throat), and pelvic health therapies. It offers stroke treatment devices like Solitaire and Pipeline, sinus implants like Propel, and bladder control systems like InterStim. These minimally invasive solutions address critical conditions and improve quality of life.• Neuromodulation: Neuromodulation provides implantable systems for managing chronic pain, movement disorders, and epilepsy. It includes spinal cord stimulators (e.g., Intellis, Inceptiv), deep brain stimulation (e.g., Percept), and drug infusion pumps (e.g., SynchroMed). These technologies personalize therapy using real-time data.Medical Surgical: The Medical Surgical segment supports hospitals and surgical centers with advanced tools and monitoring systems. It includes Surgical & Endoscopy and Acute Care and Acute Care & Monitoring sub-segments. This segment offers robotic-assisted surgery, AI-powered endoscopy, and patient monitoring solutions. In FY25, it generated $8.4 billion in revenue (25.1% of total revenue), a decrease of 0.1%.• Surgical & Endoscopy (SE): SE provides advanced surgical instruments and digital surgery platforms. It includes stapling systems (e.g., Tri-Staple), vessel sealers (e.g., LigaSure), robotic-assisted surgery (Hugo RAS), and AI-powered endoscopy (GI Genius). These tools enhance surgical precision and efficiency.• Acute Care & Monitoring (ACM): ACM focuses on patient monitoring and respiratory care. It includes pulse oximetry (Nellcor), capnography (Microstream), airway management (Shiley), and brain monitoring (BIS). These solutions help clinicians manage critical care and reduce complications.
Diabetes: The Diabetes segment is dedicated to managing Type 1 and Type 2 diabetes through smart, connected technologies. It includes insulin pumps (e.g., MiniMed 780G), continuous glucose monitoring (CGM) systems (e.g., Guardian), and smart insulin pens (e.g., InPen). In FY25, the segment generated $2.8 billion in revenue (8.2% of total revenue), growing 10.7%. Medtronic's diabetes solutions aim to automate insulin delivery and simplify disease management. The MiniMed 780G system features SmartGuard technology, which adjusts insulin every 5 minutes and includes a meal detection algorithm. The Guardian CGM system provides real-time glucose data, while the InPen smart pen integrates with CGM to guide dosing. Medtronic is focused on expanding access to automated insulin delivery systems and competing with pharmaceutical alternatives by emphasizing long-term glycemic control and patient empowerment.
Revenue Trend and Adjusted Operating Profit vs. Margin Trend
4Q25
Total revenue grew by 3.9% YoY to $8.9 billion (+1.1% vs. consensus), driven by strong performance in Cardiovascular and Diabetes segments. International markets and new product launches made significant contributions to the growth. Cardiovascular segment revenue grew 6.6% YoY to $3.3 billion, driven by a 9.2% YoY increase in the Cardiac Rhythm & Heart Failure segment, a 6.9% YoY increase from the Structural Heart & Aortic segment, offset by a 0.2% YoY decline in the Coronary & Peripheral Vascular segment. Neuroscience segment revenue increased 2.9% YoY to $2.6 billion, driven by a 4.0% YoY increase in the Cranial & Spinal Technologies segment, a 9.5% YoY increase in the Neuromodulation segment, offset by a 2.4% YoY decline in the Specialty Therapies segment.
Medical Surgical segment revenue improved 0.6% YoY to $2.2 billion, driven by a 0.2% YoY increase in the Surgical & Endoscopy segment, and a 6.3% YoY increase in the Acute Care & Monitoring segment. Diabetes segment revenue grew 10.3% YoY to $728.0 million, driven by strong US adoption of the MiniMed 780G system with high Continuous Glucose Monitor attachment and international pump upgrades to the Simplera Sync sensor.
Adjusted operating income grew 7.6% YoY to $2.5 billion (-0.3% vs. consensus), and the corresponding margin improved ~94 bps to 27.8%, driven by strong revenue growth across key portfolios and disciplined expense management. Operating leverage from higher sales and lower SG&A as a percentage of revenue also contributed to margin expansion. Adjusted net income increased 7.8% YoY to $2.1 billion (+2.7% vs. consensus), and the corresponding margin grew ~84 bps to 23.3%. Adjusted diluted earnings per share came in at $1.62 (4Q24: $1.46), beating the consensus estimates by 2.7%.
4Q25 Revenue
FY25
Total revenue grew by 3.6% to $33.5 billion (+0.1% vs. consensus), driven by strong performance in Cardiovascular and Diabetes segments, with notable growth in Cardiac Ablation. Continued innovation, international expansion, and new product approvals also supported overall growth. Cardiovascular segment revenue grew 5.5% to $12.5 billion, driven by a 6.6% increase in the Cardiac Rhythm & Heart Failure segment, a 2.3% increase from the Coronary & Peripheral Vascular segment, offset by a 0.1% decline in the Structural Heart & Aortic segment. Neuroscience segment revenue increased 4.7% to $9.9 billion, driven by a 4.6% increase in the Cranial & Spinal Technologies segment, a 10.7% increase in the Specialty Therapies segment, and a 1.2% growth in the Neuromodulation segment.
Medical Surgical segment revenue declined 01% to $8.4 billion, due to 0.2% decline in the Surgical & Endoscopy segment, and offset by 0.1% growth in the Acute Care & Monitoring segment. Diabetes segment revenue grew 10.7% to $2.7 billion. Adjusted operating income grew 4.5% to $8.6 billion (in line with consensus), and the corresponding margin improved ~23 bps to 25.8%, driven by strong revenue growth and lower SG&A expenses. Adjusted net income increased 2.3% to $7.1 billion (+0.8% vs. consensus), while the corresponding margin contracted ~27 bps to 21.1%. Adjusted diluted earnings per share came in at $5.49 (FY24: $5.20), beating the consensus estimates by 0.6%.
FY25 Revenue
Company DescriptionMedtronic plc (Parent)
Medtronic plc, headquartered in Galway, Ireland, is the world's leading healthcare technology company, committed to alleviating pain, restoring health, and extending life. With over 95,000 employees across more than 150 countries, Medtronic delivers innovative solutions for more than 70 health conditions. The company operates through four primary segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. These segments encompass a wide range of technologies, including cardiac rhythm devices, spinal and brain therapies, surgical tools, and insulin delivery systems.
New Diabetes Company (Spin-Off)
The New Diabetes Company will emerge as a leading global direct-to-consumer diabetes care provider, uniquely offering a comprehensive ecosystem for intensive insulin management. With a portfolio that includes insulin pumps, continuous glucose monitoring (CGM) systems, and digital health solutions, it empowers individuals to manage diabetes with greater ease and freedom. Backed by a dedicated team of over 8,000 employees and a robust global infrastructure, the company is poised to accelerate innovation in Automated Insulin Delivery and Smart Multiple Daily Injections (MDI).
Organization Structure

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why these actors and ‘SmartLess' podcast hosts want to help you pay less for cell service
Why these actors and ‘SmartLess' podcast hosts want to help you pay less for cell service

CNN

time21 minutes ago

  • CNN

Why these actors and ‘SmartLess' podcast hosts want to help you pay less for cell service

The latest celebrity start-up trend is no longer tequila. It's telecom. Actors Sean Hayes, Will Arnett and Jason Bateman — who host the popular 'SmartLess' podcast — are launching a wireless service as an alternative to pricier unlimited data plans from major carriers like Verizon, T-Mobile or AT&T. The decision to start the company, called SmartLess Mobile, came from a simple realization: while industry giants generally push unlimited plans, most people don't actually use that much data. Even if they're glued to their phones. 'Most Americans spend almost 90% of their time under Wi-Fi. Their mobile device very seldom actually uses the actual wireless network,' said SmartLess CEO Paul McAleese, a telecom industry veteran who co-founded the company with the actors. Research published last year by the consultancy group OpenSignal found that most mobile customers spend between 77% and 88% of their on-screen time connected to a Wi-Fi network. SmartLess Mobile offers wireless plans starting at $15 per month for 5 gigabytes of high-speed data, going up to $30 monthly for 30 gigabytes. By contrast, starter unlimited plans from the major carriers range from around $35 to $65 per month. McAleese said he and Arnett started discussing the idea after the actor bought a new phone for his teenage son and was sold an unlimited plan that cost around $70 monthly. (Arnett previously served as a spokesperson for Canadian telecom giant Shaw Communications; McAleese is the company's former president.) 'And (Arnett) goes, 'Geez, it's awfully expensive,'' McAleese said in an interview with CNN. 'And I said, 'Your boy spends almost his entire life under Wi-Fi. He's at home, he's at school … he's never going to be on the network. Why would you buy all that?'' SmartLess Mobile joins a growing slate of celebrity-backed wireless carriers, including Consumer Cellular, with longtime spokesperson Ted Danson, and Ryan Reynolds' Mint Mobile, which was acquired by T-Mobile in 2023. These providers, known as mobile virtual network operators (or MVNOs), lease access to a major telecom provider's spectrum — SmartLess plans will run on T-Mobile's 5G network — and can often charge lower prices because they don't have to manage the physical infrastructure. The services have gained popularity as cell phone technology has advanced. Most phones now have digital SIM cards, making it easier for consumers to switch carriers without having to visit a retail store. And the proliferation of Wi-Fi infrastructure everywhere from subways to restaurants means many people have lesser data needs. If their partner network goes down, MVNOs do risk being the ones customers blame for losing missing service. And limited data plans aren't necessarily for everyone — ride-share drivers and delivery couriers likely use a lot more data than people who work from home or from an office with a Wi-Fi network. But the primary 'uphill battle for any MVNO is to stand out in the space,' said Jeffrey Moore, principal at wireless industry research firm Wave7, because the industry giants have much more name recognition. Major carriers also entice customers with deals on new phones, which they practically give away for free if consumers join their network. Smaller carriers 'have to stand out either in terms of offerings or in terms of marketing,' Moore said. That's where celebrity endorsements come in. SmartLess already has a significant built-in audience; the podcast ranks among the top 20 most popular shows on Apple Podcasts. And Arnett, Hayes and the SmartLess podcast have more than 2 million combined Instagram followers. 'Whether by luck or by design, they also have a brand name that has both 'smart' and 'less' in the name,' McAleese said, 'which, if you're going to be a challenger brand in this day and age, those are two pretty good head starts.' The team plans to start discussing SmartLess Mobile on the podcast in the coming weeks, he said. And the SmartLess hosts' involvement in the new carrier goes beyond typical celebrity endorsements, McAleese said. Hayes, Arnett and Bateman had already turned down the opportunity to lend their names to other types of products, and they've been involved in everything from financing to marketing the new company. 'They rely on the category for what is now one of their primary professional pursuits, which is the podcast, this is how people consume their product,' McAleese said. 'These guys are master storytellers, and they have the brand ethos of sort of an honest broker. I think it's just a perfect marriage.'

Evening Edition: Long-Term Economic Impact Of Social Unrest
Evening Edition: Long-Term Economic Impact Of Social Unrest

Fox News

time27 minutes ago

  • Fox News

Evening Edition: Long-Term Economic Impact Of Social Unrest

With violent protestors talking to the streets of Los Angeles, burning vehicles, damaging businesses and property, the economic impact begins to come into the forefront. President Trump activated the National Guard and has sent hundreds of Marines to establish order. The L.A. riots, reminiscent of those that took place five years ago in Minneapolis that caused a half a billion dollars in economic losses, could impact local businesses and the economy for years to come FOX's John Saucier speaks with Pierre Debbas, an attorney and real estate expert, and Managing Partner of Romer Debbas, LLP, who says unrest in major cities has a long, negative ripple effect on small businesses and real estate values. Click Here⁠⁠⁠ To Follow 'The FOX News Rundown: Evening Edition' Learn more about your ad choices. Visit

AWS and national lab team up to deploy AI tools in pursuit of fusion energy
AWS and national lab team up to deploy AI tools in pursuit of fusion energy

Geek Wire

time27 minutes ago

  • Geek Wire

AWS and national lab team up to deploy AI tools in pursuit of fusion energy

Sustainability: News about the rapidly growing climate tech sector and other areas of innovation to protect our planet. SEE MORE Lawrence Livermore National Laboratory's National Ignition Facility in Livermore, Calif. (LLNL Photo) Amazon Web Services is teaming up with Lawrence Livermore National Laboratory — home to the world's only facility to achieve fusion ignition — to develop artificial intelligence tools to advance the lab's efforts, the two announced today. AWS and LLNL's National Ignition Facility are working together to build an AI-driven troubleshooting and reliability system, and have already deployed generative AI capabilities into the fusion lab's operations. The focus is on using AI to produce real-time solutions to anomalies that arise in the research and addressing increasing operational demands. More than two years ago, NIF reported that it had produced more energy from a fusion reaction than went into it, an accomplishment known as ignition. Since then, the facility has hit that mark seven additional times, most recently in April when it nearly tripled the amount of energy produced in December 2022. Researchers internationally are trying to recreate the fusion reactions that power the Sun — developing 'star in a jar' technologies that will allow humanity to produce nearly limitless clean energy on Earth. That power is increasingly in demand as data centers continue expanding and other sectors of the economy are electrifying their operations. In the new partnership with the federal lab, AWS's AI could help solve the very energy consumption problems it is helping to create. The National Ignition Facility has hit ignition eight times in fusion experiments conducted at LLNL. (LLNL Chart) 'I'm excited to unleash the superpower that is AI on NIF operations,' said Kim Budil, director of LLNL, in a statement. 'By leveraging our extensive historical data through advanced AI techniques, we're solving today's problems faster and paving the way for predictive maintenance and even more efficient operations in the future.' Last week, Washington state companies Helion Energy, Zap Energy and Avalanche Energy participated in a Seattle-area summit to share their progress in working towards commercialized fusion. In the past they celebrated NIF's experiments as a validation that their ambitions are possible. No other facility anywhere has demonstrated fusion ignition, and NIF's objective is strictly research, as opposed to building reactors to put power on the grid. One of the interesting applications being pursued at NIF is unleashing AI on more than 98,000 archived problem logs stretching back 22 years. The documents are a trove of lessons learned, including symptoms, causes and the steps taken to fix the problems. A release from the California-based national lab said the partnership could 'establish a new standard for AI application in high-stakes scientific facilities and may influence operational approaches at other national laboratories.' David Appel, vice president of U.S. Federal Sales at AWS, called LLNL 'an innovation and scientific powerhouse, and we're extraordinarily proud of our partnership together.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store